Abstract

EBOLA VIRUS DISEASE

Pravallika Reddy*, H.Padmalatha, G.Shwetha Reddy, N.Nirmala, B.Swathi

Abstract

The first vaccine designed to prevent infection with the lethal Ebola virus has passed initial safety tests in humans and has shown promising signs that it may indeed protect people from contracting the disease. Ebola viruses are highly lethal filo viruses that cause hemorrhagic fever in humans and non-human primates. With no approved treatments or preventatives, the development of an anti-ebola virus therapy to protect against natural infections and potential weaponization is an urgent global health need. In July 2014, as the Ebola virus disease (Ebola) epidemic expanded in Guinea, Liberia, and Sierra Leone, an air traveler brought Ebola to Nigeria and two American health care workers in West Africa were diagnosed with Ebola and later medically evacuated to a U.S. hospital. Ebola virus disease (Ebola) is a multisystem disease caused by a virus of the genus Ebola virus. In late March 2014, Ebola cases were described in Liberia, with epicenters in Lofa County and later in Montserrado County. While information about case burden and health care infrastructure was available for the two epicenters, little information was available about remote counties in southeastern Liberia.

Keywords: Ebola virus.